Zelboraf

Zelboraf (Vemurafenib) is a cancer medication prescribed for the treatment of unresectable or metastatic melanoma, in which cells of the BRAF V600 mutation were detected.

Zelboraf (Vemurafenib) is an inhibitor of serine threonine kinase, which is encoded by the BRAF gene. Mutations in the BRAF gene result in constitutive activation of BRAF proteins, which may cause cell proliferation in the absence of associated growth factors.

Preclinical data obtained in biochemical analyzes indicate that vemurapenib potentially suppresses BRAF kinases with activating mutations in codon 600.

Always follow your doctor`s instructions when using Zelboraf (Vemurafenib) to get the safest and most effective results from treatment.

Treatment with vemurafenib should be initiated and supervised by a qualified physician experienced in the appointment of antitumor drugs.

Before initiating Zelboraf (Vemurafenib), the presence of a BRAF V600 mutation in tumor cells should be confirmed using a validated method of study.

The recommended dose of Zelboraf (Vemurafenib) is 960 mg (4 tablets of 240 mg) twice a day; daily dose - 1,920 mg. Zelboraf (Vemurafenib) can be taken with or without food, but you must avoid taking both daily doses consistently.

Zelboraf (Vemurafenib) is for oral use. Pills should be swallowed whole, with water, do not chew or break.

If the next dose is missed, it can be taken later to maintain the dosage regimen twice a day, but the interval between taking the missed dose and taking the next dose should be at least 4 hours. You should not take both doses at the same time.

There is no specific antidote that could be used in cases of overdose with Zelboraf (Vemurafenib). In the event of side effects, symptomatic treatment should be prescribed. Dose-limiting toxic effects for vemurafenib include skin rash with itching and fatigue. In clinical studies of vemurafenib, cases of overdose have not been reported. In the event of a suspicion of overdose, use of tamrafenib should be discontinued and supportive therapy administered.

The use of Zelboraf (Vemurafenib) may cause side effects in some patients including:

• arthralgia
• rash
• weakness
• nausea and vomiting
• photosensitivity reaction
• itching
• alopecia

Contact your doctor immediately if you experience any serious or worrying symptoms.

Zelboraf (Vemurafenib) should not be used by patients who are hypersensitivity to vomurafenib and other components of the drug.

Strictly use Zelboraf (Vemurafenib) as prescribed and follow all instructions provided by your doctor. Safe, suitable, and optimum dosage can vary and is dependent on the patient`s health and medical history, as well as the condition you are treating.

Safety and efficacy of vemurafenib in children under 18 years of age have not been established.